PODD Quote, Financials, Valuation and Earnings

iRhythm Technologies has a net margin of 6.22% compared to Insulet's net margin of -19.35%. Insulet's return on equity of 36.9% beat iRhythm Technologies's return on equity of -112.03%.

Insulet has a consensus price target of $336.85, signalling upside risk potential of 16.85%. On the other hand iRhythm Technologies has an analysts' consensus of $145.67 which suggests that it could grow by 6.33%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

Insulet has a beta of 1.346, which suggesting that the stock is 34.619% more volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.413, suggesting its more volatile than the S&P 500 by 41.267%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are larger than iRhythm Technologies quarterly revenues of $158.7M. Insulet's net income of $35.4M is higher than iRhythm Technologies's net income of -$30.7M. Notably, Insulet's price-to-earnings ratio is 51.85x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.70x versus 6.94x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 6.22% compared to Insulet's net margin of -45.89%. Insulet's return on equity of 36.9% beat Masimo's return on equity of -39.91%.

Insulet has a consensus price target of $336.85, signalling upside risk potential of 16.85%. On the other hand Masimo has an analysts' consensus of $184.37 which suggests that it could grow by 15.63%. Given that Insulet has higher upside potential than Masimo, analysts believe Insulet is more attractive than Masimo.

Insulet has a beta of 1.346, which suggesting that the stock is 34.619% more volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.716%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are larger than Masimo quarterly revenues of $372M. Insulet's net income of $35.4M is higher than Masimo's net income of -$170.7M. Notably, Insulet's price-to-earnings ratio is 51.85x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.70x versus 4.38x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 6.22% compared to Insulet's net margin of 28.26%. Insulet's return on equity of 36.9% beat ResMed's return on equity of 25.76%.

Insulet has a consensus price target of $336.85, signalling upside risk potential of 16.85%. On the other hand ResMed has an analysts' consensus of $269.49 which suggests that it could grow by 5.99%. Given that Insulet has higher upside potential than ResMed, analysts believe Insulet is more attractive than ResMed.

Insulet has a beta of 1.346, which suggesting that the stock is 34.619% more volatile than S&P 500. In comparison ResMed has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.603%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.83% to investors and pays a quarterly dividend of $0.53 per share. Insulet pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Insulet quarterly revenues are $569M, which are smaller than ResMed quarterly revenues of $1.3B. Insulet's net income of $35.4M is lower than ResMed's net income of $365M. Notably, Insulet's price-to-earnings ratio is 51.85x while ResMed's PE ratio is 28.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.70x versus 7.47x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 6.22% compared to Insulet's net margin of -55.69%. Insulet's return on equity of 36.9% beat Tandem Diabetes Care's return on equity of -81.14%.

Insulet has a consensus price target of $336.85, signalling upside risk potential of 16.85%. On the other hand Tandem Diabetes Care has an analysts' consensus of $31.70 which suggests that it could grow by 101.27%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Insulet has a beta of 1.346, which suggesting that the stock is 34.619% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.478, suggesting its more volatile than the S&P 500 by 47.763%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $569M, which are larger than Tandem Diabetes Care quarterly revenues of $234.4M. Insulet's net income of $35.4M is higher than Tandem Diabetes Care's net income of -$130.6M. Notably, Insulet's price-to-earnings ratio is 51.85x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.70x versus 1.05x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.